Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
DRIO Catalyst Timeline
Dated clinical, regulatory and corporate events for DarioHealth Corp.
Past FDA Catalysts and PDUFA Decisions
How DRIO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
DarioHealth Corp. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every DRIO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Dario | Type 2 Diabetes | 2023-10-17 | hospital readmission reduction: 36%; hospital days reduction: 1.6; Hb A1c control improvement: 9%; poor control reduction: 13%Read More | New Research Shows 36% Reduction in 30-Day Hospital Readmission Rate for Dario Users with Type 2 DiabetesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Matheis DennisDirector | Buy | 14,430 43,026 held | $6.93 | 07/23/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DRIO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0 % | 1.29 M | 313.87 K | -4.27% ( -14.00 K) |
Ownership Trends
DRIO Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How DRIO ranks across every disease it competes in
DRIO News
Dario Secures Second Women's Health Contract in Just Weeks with The Minnesota Star Tribune
DarioHealth Corp. announced an expanded contract with The Minnesota Star Tribune to implement its Dario Women program, aimed at supporting women through perimenopause and menopause. This marks the second adoption of the program within weeks, reflecting strong demand for women's health solutions. The program will be available to eligible employees starting January 2027.
Read more →Dario Presents New Research at ISPOR Europe 2026 Validating a Biometric-Driven Approach to Estimating Healthcare Cost Savings and ROI - Consistent with Published Benchmarks and Without Waiting for Claims Data
DarioHealth presented research at ISPOR Europe 2026 detailing a model to estimate cost savings from biometric improvements. The method translates changes in blood pressure and glucose into projected healthcare expenditure reductions. This approach allows purchasers to evaluate program value without waiting for delayed medical claims data.
Read more →DarioHealth Reports Third Quarter 2026 Financial Results: Year-over-Year Revenue Growth and Operating Expense Reduction
DarioHealth reported a 6% year-over-year revenue growth for Q3 2026, reaching $5.3 million. The company also achieved a 15% reduction in operating loss and a stable gross margin of 59%. Dario anticipates further revenue acceleration driven by new enterprise customers and multi-condition expansions, including Dario Women™ and Dario Sleep.
Read more →Dario Names Veteran Healthcare Executive John R. Palumbo Chairman of the Board as Company Positions Itself to Lead the Convergence of Consumer and Payer-Funded Care
DarioHealth Corp. appointed John R. Palumbo as Chairman of the Board, effective November 3, 2026. This move aligns with the convergence of consumer and payer-led healthcare, as Dario aims to enhance chronic care management. Palumbo, with over 40 years of experience, will lead the Board in capturing strategic opportunities in this evolving market.
Read more →DarioHealth to Report Third Quarter 2026 Results on Thursday, November 12, 2026
DarioHealth Corp. will announce its financial results for Q3 2026 on November 12, 2026. The company will host a conference call at 8:30 a.m. Eastern Time, featuring key executives. DarioHealth focuses on AI-driven healthcare solutions to improve outcomes for chronic conditions.
Read more →Dario Expands Contract with a Leading Regional Grocery Retailer, Adding Women's Digital Health and Clinical Care Program
DarioHealth Corp. announced a contract extension with a regional grocery retailer to include its Dario Women program, aimed at supporting women during perimenopause and menopause. This expansion follows the success of Dario's cardiometabolic program and reflects strong employee demand for women's health solutions. The program will launch in January 2027, enhancing Dario's multi-condition platform.
Read more →DarioHealth Announces Independent Aon Analysis that Supports Estimated 2.5%-7.2% In-Year Reduction in Total Healthcare Costs
DarioHealth Corp. announced the results of an independent review by Aon, which estimates a potential annual reduction in healthcare costs of 2.5% to 7.2% for users of its digital health platform. The analysis suggests significant savings for a typical 20,000-life population, amounting to $3.8 million to $10.8 million. Aon highlighted the platform's effectiveness in managing multiple chronic conditions and providing direct access to physicians, although the review had limitations regarding data verification.
Read more →Dario Wins Contract with One of New Jersey's Largest Health Plans Representing 1.5 Million Covered Lives
DarioHealth Corp. announced a contract with a major New Jersey health plan, covering 1.5 million lives. This agreement, facilitated through Amwell, is set to launch in Q1 2027 and will enhance Dario's distribution strategy. It marks the third significant contract in the past year, expanding their reach in the healthcare market.
Read more →DarioHealth Reports Second Quarter 2026 Financial Results
DarioHealth Corp. reported its second quarter 2026 financial results, showing a revenue of $5.2 million, a decrease from the previous quarter. The company achieved a gross margin of 62%, up from 57% in Q1 2026, and reduced its operating loss by 30% year-over-year. DarioHealth is expanding its multi-condition platform and has secured significant new clients, enhancing its revenue potential.
Read more →Dario Expands Provider-Backed Cardiometabolic Platform with New Women's Health and Sleep Solutions Aligning with Client Demand
DarioHealth Corp. announced the launch of Dario Women™ and Dario Sleep™, expanding its cardiometabolic platform. These new programs aim to improve health outcomes through AI-driven engagement and provider-backed care. Revenue from these initiatives is expected to begin in Q4 2026, addressing significant clinical needs for employers and health plans.
Read more →DarioHealth to Report Second Quarter 2026 Results on Tuesday, August 11, 2026
DarioHealth Corp. will announce its financial results for Q2 2026 on August 11, 2026. The company, known for its AI-driven healthcare solutions, will host a conference call at 8:30 a.m. ET, featuring key executives. This event aims to provide insights into the company's performance and future strategies.
Read more →Dario Launches Integrated GLP-1 Program, Combining Its Digital Chronic Care Platform with Provider-Backed Clinical Care in a Single End-to-End Experience
DarioHealth has launched its Integrated GLP-1 Program, combining digital chronic care with provider-backed clinical services. This initiative aims to meet the needs of consumers seeking GLP-1 therapies amid changing reimbursement models. The program will be available through various channels starting in Fall 2026, with anticipated revenue growth into 2027.
Read more →Dario Announces Pricing of a $23.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
DarioHealth Corp. has announced a registered direct offering of common stock, raising approximately $23.5 million. The offering, priced at $6.80 per share, involves participation from existing long-term investors and new institutional investors. The funds will be utilized for working capital, investments, and general corporate purposes, with the closing expected on July 23, 2026.
Read more →Fortune 50 Employer Awards Dario Contract to Deliver AI-Powered Cardiometabolic Care Platform
DarioHealth Corp. announced a contract with a Fortune 50 employer to provide its AI-powered cardiometabolic care platform for over 100,000 employees. The program, launching in Fall 2026, aims to improve health outcomes and reduce costs associated with chronic conditions like diabetes and hypertension. Revenue is expected to begin by the end of 2026 and increase through 2027.
Read more →Dario Expects Proprietary AI Engine DarioIQ™ to Increase Recurring Revenue from Existing Customers by 10-15%
DarioHealth Corp. expects its AI platform, DarioIQ, to boost annual B2B2C recurring revenue by 10-15% from existing customers. The platform enhances member engagement by 40% and retention by 20%, leveraging over 13 billion healthcare data points. The company aims to improve clinical outcomes and ROI while expanding its market presence.
Read more →Dario Signs New Agreement with a Major Health Insurer in Arizona Representing Hundreds of Thousands of Lives Through Amwell Partnership
DarioHealth Corp. has signed a new agreement with a major health insurer in Arizona through its partnership with Amwell. This agreement allows Dario's cardiometabolic digital health solutions to be offered to a large population of self-insured employers. The initiative aims to reduce cardiometabolic risks and costs while providing tailored health solutions to meet specific employer needs.
Read more →Top National Health Plan Extends Agreement for Mental Health and Expands Dario Partnership into Cardiometabolic Care, Demonstrating Successful Multi-Condition Growth Strategy
DarioHealth Corp. has expanded its partnership with a major U.S. health insurer, adding hypertension solutions to its existing behavioral health offerings. This extension is expected to triple revenue opportunities under this customer relationship, reinforcing Dario's multi-condition care strategy. The company aims to improve health outcomes while reducing costs through integrated care solutions.
Read more →Dario Appoints Former Humana Chief Compliance Officer Sean O'Reilly to Advisory Board to Support Strategic Growth and Healthcare Partnerships
DarioHealth Corp. has appointed Sean O'Reilly, former Chief Compliance Officer at Humana, to its Advisory Board. His extensive experience in healthcare compliance and risk management is expected to support Dario's growth strategy and enhance its relationships with health plans, employers, and providers. O'Reilly's background in leveraging AI for value-based care aligns with Dario's mission to improve healthcare outcomes.
Read more →Dario Announces Strategic Collaboration with Beluga Health to Deliver Provider-Backed, Integrated Care at Scale
DarioHealth Corp. has announced a strategic collaboration with Beluga Health to enhance its digital health solutions. This partnership aims to provide a provider-backed, integrated care model that combines Dario's chronic care platform with Beluga's clinical network. The collaboration is expected to improve member engagement, lower healthcare costs, and expand into new markets, positioning Dario as a key player in value-based care.
Read more →Dario Presents Four Studies at American Diabetes Association Scientific Sessions Highlighting Commercial and Clinical Value of its Digital Health Platform
DarioHealth Corp. presented notable findings at the American Diabetes Association Scientific Sessions, showcasing the effectiveness of its digital health platform in managing chronic conditions like diabetes and obesity. The studies highlighted that sustained engagement with the platform leads to improved clinical outcomes, as evidenced by significant weight loss and reductions in hospitalizations among high-risk patients. Findings indicate potential cost savings for payers and a compelling case for enterprise buyers to adopt integrated solutions for better patient management across multiple chronic conditions. With a total of 27 studies presented over eight years, Dario reinforces its strategic move towards value-based healthcare.
Read more →